DEVELOPMENT OF IN VITRO DIAGNOSTICS FOR ANTIMICROBIAL RESISTANCE ESCHERICHIA COLI

大肠杆菌耐药性体外诊断的开发

• 批准号: 10912990
• 负责人: RANGARAJAN SAMPATH
• 金额: $ 542.27万
• 依托单位: SIEMENS HEALTHCARE DIAGNOSTICS INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-24 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10912990
• 关键词: Area; Bacterial Drug Resistance; Blood; Detection; Development; Diagnostic; Emerging Communicable Diseases; Escherichia coli; Infection; Methods; Nucleic acid sequencing; Performance; Proteins; antimicrobial resistant infection; biodefense; diagnostic technologies; improved; in-vitro diagnostics; microbial; pathogen

To support the development of promising diagnostics technologies for antimicrobial-resistant infections, emerging and reemerging infectious diseases and biodefense pathogens. Areas of support may focus on improving performance of agnostic nucleic acid sequencing solutions on commercial platforms; methods that improve protein analyte detection; and efforts to improve direct-from-blood or other biofluid detection and identification of microbial infection.

支持开发有前景的诊断技术，用于治疗耐抗生素感染、新发和再发传染病以及生物防御病原体。支持领域可能集中在提高商业平台上不可知核酸测序解决方案的性能;改进蛋白质分析物检测的方法;以及改进直接来自血液或其他生物流体的检测和微生物感染鉴定的努力。